Philadelphia, Pennsylvania
Phase 3 cancer trials in Philadelphia, PA
73 Phase 3 cancer studies are recruiting participants at sites in Philadelphia as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Philadelphia at a glance
- 73 studies are recruiting at a site in Philadelphia.
- By phase: Phase 2/3 (8), Phase 3 (65).
- By sponsor: industry (41), university, hospital or other (24), government (8).
- By research area: Lung Cancer (20), Breast Cancer (17), Lymphoma (13), Melanoma (11), Prostate Cancer (7), Pancreatic Cancer (5).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Philadelphia
Basic details from each study's public record (the 30 most recently updated of 73). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049)
- Registry record
- NCT06393374 · updated
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT07391774 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- University of Pennsylvania Abramson Cancer Center
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Fox Chase Cancer Center · Jefferson Torresdale Hospital · Temple Health - Chestnut Hill Hospital
- Registry record
- NCT05879926 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Jefferson Hospital Northeast · Thomas Jefferson University - Clinical Research Institute
- Registry record
- NCT07174336 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Lung cancer studies recruiting in Philadelphia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Thomas Jefferson University - Clinical Research Institute ( Site 0147)
- Registry record
- NCT06422143 · updated
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NovoCure GmbH
- Study site
- Abramson Cancer Center
- Registry record
- NCT06216301 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Perelman Center for Advanced Medicine ( Site 3205)
- Registry record
- NCT07513376 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Temple University Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- ECOG-ACRIN Cancer Research Group
- Registry record
- NCT06096844 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT07100080 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT04181060 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office
- Registry record
- NCT06119581 · updated
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Jefferson Hospital Northeast · Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office
- Registry record
- NCT06890598 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Philadelphia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Penn Presbyterian Medical Center · Thomas Jefferson University Hospital · University of Pennsylvania/Abramson Cancer Center
- Registry record
- NCT04423211 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT06931340 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Penn Medicine Abramson Cancer Center
- Registry record
- NCT07164443 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Melanoma studies recruiting in Philadelphia
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University Hospital
- Registry record
- NCT07068074 · updated
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Wills Eye Hospital at Thomas Jefferson University
- Registry record
- NCT07804186 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Lymphoma studies recruiting in Philadelphia
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University Hospital
- Registry record
- NCT06337318 · updated
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- Thomas Jefferson University Hospital
- Registry record
- NCT05303519 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of Philadelphia · Saint Christopher's Hospital for Children · Thomas Jefferson University Hospital
- Registry record
- NCT05675410 · updated
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Phase 3
- Ages 1 and older
- All sexes
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study site
- Children's Hospital of Philadelphia
- Registry record
- NCT07223021 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Thomas Jefferson University Hospital · University of Pennsylvania/Abramson Cancer Center
- Registry record
- NCT03150693 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Philadelphia
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US008 · Investigative Site US043
- Registry record
- NCT07522073 · updated
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- Thomas Jefferson University
- Registry record
- NCT07562152 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Ask about studies near Philadelphia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
127 studies recruiting across 77 cities.
Pittsburgh
63 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections